

Matthias Pinter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5870099/publications.pdf>

Version: 2024-02-01

96
papers

5,565
citations

117625

34
h-index

88630

70
g-index

96
all docs

96
docs citations

96
times ranked

6551
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	4.4	25
2	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	4.4	39
3	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
4	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
5	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 399-399.	1.6	1
6	Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection. <i>Journal of Hepatology</i> , 2022, , .	3.7	2
7	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
8	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210802.	3.2	43
9	Reply to: –The CRAFTY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy–. <i>Journal of Hepatology</i> , 2022, 76, 1233-1234.	3.7	1
10	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. <i>Cancers</i> , 2022, 14, 1722.	3.7	26
11	Angiotensin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. <i>Digestive and Liver Disease</i> , 2022, 54, 1222-1229.	0.9	2
12	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child–Pugh A and B cirrhosis: A real–world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
13	Reply to: –Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?–. <i>Journal of Hepatology</i> , 2022, 76, 988-989.	3.7	0
14	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	3.7	44
15	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	5.1	11
16	Reply to: –The CRAFTY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations–. <i>Journal of Hepatology</i> , 2022, , .	3.7	0
17	Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. <i>Cancers</i> , 2022, 14, 3093.	3.7	5
18	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. <i>Liver International</i> , 2022, 42, 2501-2512.	3.9	16

#	ARTICLE	IF	CITATIONS
19	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	12.1	51
20	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021, 70, 204-214.	12.1	150
21	Alpha-fetoprotein-adjusted HCC size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 209-219.	3.8	5
22	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
23	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	3.7	96
24	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 113.	7.1	213
25	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.9	0
26	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	7.7	25
27	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
28	Cytotoxic Activity of Piperazin-2-One-Based Structures: Cyclic Imines, Lactams, Aminophosphonates, and Their Derivatives. <i>Materials</i> , 2021, 14, 2138.	2.9	6
29	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	2.5	5
30	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	3.8	22
31	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	4.3	16
32	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	3.9	36
33	A patient with liver cirrhosis and hepatic lesions. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 309-312.	0.5	0
34	A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model. <i>International Journal of Oncology</i> , 2021, 59, .	3.3	6
35	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Hepatology Communications</i> , 2021, 5, 1939-1952.	4.3	8
36	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
38	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33
39	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1485-1493.	3.7	7
40	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	7.3	112
41	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 1-11.	1.9	15
42	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	3.9	20
43	Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma". <i>Liver Cancer</i> , 2020, 9, 107-107.	7.7	0
44	Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?". <i>Liver Cancer</i> , 2020, 9, 110-111.	7.7	0
45	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020, 12, 2961.	3.7	8
46	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020, 52, 1473-1479.	0.9	6
47	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23684-23694.	7.1	32
48	Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 917-918.	3.7	0
49	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	3.7	47
50	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	4.2	12
51	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	3.9	14
52	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	3.7	17
53	Synthesis and Cytotoxic Activity of Chiral Sulfonamides Based on the 2-Azabicycloalkane Skeleton. <i>Molecules</i> , 2020, 25, 2355.	3.8	9
54	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15

#	ARTICLE	IF	CITATIONS
55	Novel reliability criteria for controlled attenuation parameter assessments for noninvasive evaluation of hepatic steatosis. United European Gastroenterology Journal, 2020, 8, 321-331.	3.8	30
56	Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.. Journal of Clinical Oncology, 2020, 38, e16668-e16668.	1.6	5
57	PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Reports, 2020, 21, e50893.	4.5	29
58	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 850-858.	3.8	18
59	Letter: programmed cell death protein-1 targeted immunotherapy for advanced hepatocellular carcinoma—authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 341-342.	3.7	0
60	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. American Journal of Transplantation, 2019, 19, 3176-3184.	4.7	60
61	Letter: programmed cell death protein-1 (PD-1) targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort—more questions than answers. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 231-232.	3.7	5
62	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver International, 2019, 39, 714-726.	3.9	49
63	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. Digestive Diseases and Sciences, 2019, 64, 3642-3651.	2.3	8
64	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. PLoS ONE, 2019, 14, e0216677.	2.5	22
65	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2164-2172.	2.8	9
66	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Digestive and Liver Disease, 2019, 51, 1144-1151.	0.9	23
67	Programmed cell death protein-1 (PD-1) targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	3.7	106
68	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 203-217.	7.7	48
69	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Scientific Reports, 2018, 8, 6220.	3.3	155
70	Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events. Clinical Cancer Research, 2018, 24, 3803-3812.	7.0	40
71	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Science Translational Medicine, 2018, 10, .	12.4	153
72	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. Memo - Magazine of European Medical Oncology, 2018, 11, 185-192.	0.5	6

#	ARTICLE	IF	CITATIONS
73	Review article: systemic treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 598-609.	3.7	131
74	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 10054-10068.	1.8	25
75	Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5959-5969.	7.0	75
76	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	3.8	49
77	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	232
78	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1732-1741.	6.4	20
79	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. <i>Oncotarget</i> , 2017, 8, 57109-57120.	1.8	5
80	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0181878.	2.5	24
81	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , 2016, 1, e000042.	4.5	194
82	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. <i>Cancer Discovery</i> , 2016, 6, 852-869.	9.4	318
83	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015, 277, 903-912.	7.3	60
84	Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2 ^{loxP/loxP} Villin-Cre mice. <i>Gut</i> , 2015, 64, 1905-1912.	12.1	26
85	Epidemiological Trends of Hepatocellular Carcinoma in Austria. <i>Digestive Diseases</i> , 2014, 32, 664-669.	1.9	10
86	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014, 60, 118-126.	3.7	105
87	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1287-1296.	3.7	139
88	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2261-2273.	7.3	288
89	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2224-2234.	7.3	101
90	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013, 62, 1634-1641.	12.1	275

#	ARTICLE	IF	CITATIONS
91	Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology, 2012, 263, 590-599.	7.3	177
92	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. Wiener Klinische Wochenschrift, 2012, 124, 395-402.	1.9	93
93	Comparative outcome of sorafenib treatment in central Europe and Russia.. Journal of Clinical Oncology, 2012, 30, e14681-e14681.	1.6	0
94	Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis. Oncologist, 2009, 14, 70-76.	3.7	169
95	Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. European Journal of Gastroenterology and Hepatology, 2008, 20, 1012-1019.	1.6	20
96	Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab. Memo - Magazine of European Medical Oncology, 0, , 1.	0.5	2